ADIPOTIDE

Background

Adipotide (also published as adipotide-1 or CKGGRAKDC-GG-D(KLAKLAK)2) was developed in the laboratories of Renata Pasqualini and Wadih Arap at MD Anderson Cancer Center, building on their broader work in vascular targeting peptides identified through phage display.

The construct has two parts:

1. A homing peptide (CKGGRAKDC) that binds prohibitin on the surface of white-adipose-tissue endothelial cells. Prohibitin distribution is surprisingly tissue-selective on the vascular endothelium.
2. A pro-apoptotic warhead (D(KLAKLAK)2) — a synthetic D-amino-acid peptide that disrupts mitochondrial membranes when delivered intracellularly.

When the conjugate binds the WAT endothelium, the warhead is internalized and triggers endothelial cell apoptosis. Loss of vasculature starves the adipose tissue and causes regression.

Mechanism in depth

The targeting mechanism is the conceptually interesting part. Prohibitin is normally a mitochondrial inner-membrane protein but is also displayed on the surface of WAT endothelium — a finding made through in vivo phage display screens. The CKGGRAKDC peptide was selected for its ability to home to WAT in living mice.

Once bound and internalized, the D(KLAKLAK)2 fragment disrupts mitochondrial membranes selectively (it is too cationic to easily cross intact plasma membranes from outside, which is why the targeting peptide is necessary). Endothelial apoptosis follows, then loss of vessels, then regression of the supplied fat pad.

This mechanism is unlike any other "weight-loss peptide" in common circulation. It is a cytotoxic, not a metabolic, intervention.

Human evidence

Effectively none in published form. One phase I trial was initiated in obese men with prostate cancer (a dual-indication context, since some prostate tumors are sensitive to the same warhead). Results have not been published in detail at the level needed for safety inference.

There are no controlled trials of adipotide in non-cancer obese adults.

Animal evidence

This is where the compelling data lives:

• Mice (Kolonin 2004) — obese mice lost weight rapidly; lean mice were unaffected; tissue specificity to WAT was demonstrated.
• Rhesus macaques (Barnhart 2011) — about 11% body weight loss in 28 days, improvements in insulin sensitivity, no central nervous system signs of malaise.
• Renal toxicity — proximal tubule damage was observed in both rodents and monkeys, dose-dependent, partially reversible. This is the safety signal that has hindered translation.

The combination of efficacy and toxicity is unusually clear. Adipotide works; the question is whether the therapeutic window is wide enough for human use.

Stack synergy

There is no reasonable empirical basis to stack adipotide with other peptides. Its mechanism is selective cytotoxicity rather than metabolic modulation, so the synergy logic that applies to GH-axis or AMPK stacks does not apply here. Combining it with other compounds primarily compounds risk without an obvious mechanistic benefit.

Open questions

• Can the therapeutic window be widened (formulation, delivery, dosing)?
• Is the renal toxicity mechanistic (off-target prohibitin binding in kidney) or a concentration effect (clearance pathway saturation)?
• What is the long-term outcome — do destroyed fat pads regenerate, or is the loss durable?
• Are there sub-populations (e.g., specific obesity phenotypes) where the risk/benefit makes sense?

For a non-research user, the honest summary is that adipotide is a compelling preclinical compound with a documented serious safety signal and no validated human protocol. The barrier to use is not just regulatory.